Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

711158

registered interest
date	14/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Homes: Fees and Charges
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in the light of research from Reform indicating that the number of deferred payments issued by local authorities has not risen since 2012, whether they plan to widen access to the Deferred Payment Scheme by raising the £23,500 means threshold.
tabling member printed	Lord Lipsey
uin	HL6046
answer	answer is ministerial correction date of answer 27/03/2017 answer text <p>The Care Act 2014 introduced universal Deferred Payment Agreements (DPAs) so that people should not be forced to sell their homes in their lifetimes to pay for care. The eligibility criteria for DPAs are designed to ensure that they are available to those who would otherwise be at risk of having to sell their homes.</p><p>The Department is continuing to monitor the success of the scheme, and data on the uptake of DPAs across all local authorities will be available later this year.</p> answering member printed Lord O'Shaughnessy question first answered 27/03/2017 10:41:13 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2492 label Biography information for Lord Lipsey

711166

registered interest
date	14/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospital Wards: Gender
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 13 March (HL5692), in the context of NHS hospital sleeping accommodation, what is their definition of the opposite sex of (1) men, and (2) women.
tabling member printed	Lord Tebbit
uin	HL6054
answer	answer is ministerial correction date of answer 22/03/2017 answer text <p>As set out in the guidance <em>Eliminating mixed sex accommodation in hospitals</em>, it is for each trust to determine how best to accommodate patients, taking into account national guidance on action to eliminate mixed sex accommodation, the relevant quality and safety standards, and patients’ own preferences. A copy of the guidance is attached.</p> answering member printed Lord O'Shaughnessy question first answered 22/03/2017 12:21:57 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name MSA guidance.pdf title Eliminating mixed sex accommodation
tabling member	952 label Biography information for Lord Tebbit

711182

registered interest
date	14/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Developing Countries: Smoking
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which countries the UK will be supporting as part of its international support for smoking control; and when that work will start in each country.
tabling member printed	Lord Palmer
uin	HL6070
answer	answer is ministerial correction date of answer 23/03/2017 answer text <p>The Framework Convention for Tobacco Control (FCTC) Secretariat held an application process to select 15 low to middle income countries to receive support to develop their tobacco control plans.</p><p> </p><p>The FCTC Secretariat will inform successful applicants by the end of March 2017, and publish the results on their website. The project will commence work with those selected countries in year two of the project.</p> answering member printed Lord O'Shaughnessy question first answered 23/03/2017 15:41:17 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3192 label Biography information for Lord Palmer

711183

registered interest
date	14/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they have to restrict patient access to new NICE-approved treatments for a period of time in excess of one year if the cost of introducing such treatments exceeds a given financial threshold in their early years; and whether any such plans to restrict patient access could be implemented without legislation.
tabling member printed	Lord Warner
uin	HL6071
answer	answer is ministerial correction date of answer 28/03/2017 answer text <p>From 1 April, a ‘budget impact test’ will be introduced for products assessed through the National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technologies programmes. The budget impact test has been developed within the existing legislative framework for the funding requirement. The National Health Service spent over £15 billion on medicines in 2015/16, a 20% increase since 2010/11, and the purpose of the budget impact test is to help to manage the introduction of high budget impact products into the NHS, and to ensure that their introduction does not distort the NHS’s ability to fund other priorities.</p><p> </p><p>Where the budget impact of a technology being evaluated by NICE is expected to have a net budget impact that is £20 million or greater in any of the first three years, NHS England will seek to have a commercial discussion with the company in order to manage the introduction of the high budget impact product into the NHS. In circumstances where a commercial arrangement is unable to be reached, NHS England may make a case to NICE for a longer implementation period, normally up to a maximum of three years, during which the product would have a phased introduction. It should be noted that £20 million is not the maximum amount that the NHS would commit to funding a new technology in any one financial year.</p> answering member printed Lord O'Shaughnessy question first answered 28/03/2017 15:39:37 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1732 label Biography information for Lord Warner